Monday, 04 March 2024

CEPI Call provides up to $140 M in funding to vaccine developers

29 January 2021 | News

Purpose of Call is to fill in current clinical research and development gaps to expand access to COVID-19 vaccines

Norway based CEPI, the Coalition for Epidemic Preparedness Innovations, has opened a new funding opportunity to support the rapid generation of additional clinical research on COVID-19 vaccines.

Complementary to ongoing vaccine R&D efforts, the purpose of the new Call is to provide critical evidence to address current gaps in our clinical knowledge of vaccine performance both now and in the long-term, in order to expand access to COVID-19 vaccines as part of the global vaccination rollout.

Up to $140 million, contingent upon the availability of funds, is to be made available to scientific groups worldwide to carry out the supporting research on COVID-19 vaccines either already available to populations in some countries under ‘emergency use approval’ or ‘conditional licensure’ or similar, or currently in clinical development.

This includes COVID-19 vaccine developers, as well as public health organisations, academic institutions and others who may not be directly carrying out their own COVID-19 vaccine development but have the capacity, ability and partnerships established to carry out research on a chosen vaccine.

As one of the global health organisations co-leading the response to the COVID-19 pandemic, CEPI is launching this Call to ensure expanding access to COVID-19 vaccines remains a global priority and to also act in its facilitating role, connecting successful applicants to initiatives and projects supported by CEPI, to advance their clinical research.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account